Pfizer Bullish on its New AIDS drug

Maraviroc is showing great results in clinical trials, the company reported today from the 14th Conference of Retroviruses and Opportunistic Infections in Los Angeles. Before the conference started, Bloomberg interiewed Kevin De Cock, Director of the World Health Organization's HIV/AIDS program, who discussed the need for new drugs to treat drug-resistant strains of HIV and tuberculosis.

Play Video

World Health Organization Kevin De Cock on Drug Resistant Strains of TB and HIV-Related TB (Part 1) - Bloomberg

Bloomberg - (BLOOM)

Feb. 26, 2007. 06:39 PM EST

Before the 14th Conference of Retroviruses and Opportunistic Infections in Los Angeles, the WHO's director of HIV/AIDS discusses needs and issues

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


  • <p>New leadership at FDA has promised to build up the science/knowledge and IT base that will make it possible for those within the Agency to have meaningful debates on safety and other issues, and for whistleblowers to make their points, and be understood by their colleagues. </p> <p>As former Commissioners recently pointed out, the FDA's budget for continuing education of staff has been cut to the bone for the past several years, at a time when the science behind cures is changing rapidly.<a href="">mcdba questions</a>// <a href="">mcitp questions</a>// <a href="">mcp questions</a>// <a href="">mcpd questions</a>// <a href="">mcsa exam questions</a>// <a href="">mcsa exam questions</a>// <a href="">mcsa 2008 prep</a>// <a href="">mcse prep</a>// <a href="">mcse 2003 papers</a>// <a href="">mcse 2008 questions</a>// <a href="">mcts questions</a>// </p>


RSS feed for comments on this page | RSS feed for all comments